000287484 001__ 287484
000287484 005__ 20250818132344.0
000287484 0247_ $$2doi$$a10.1016/S2352-3026(23)00366-6
000287484 0247_ $$2pmid$$apmid:38302221
000287484 0247_ $$2ISSN$$a2352-3026
000287484 0247_ $$2ISSN$$a2451-9960
000287484 0247_ $$2altmetric$$aaltmetric:158922923
000287484 037__ $$aDKFZ-2024-00262
000287484 041__ $$aEnglish
000287484 082__ $$a610
000287484 1001_ $$aMai, Elias K$$b0
000287484 245__ $$aElotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
000287484 260__ $$aLondon [u.a.]$$bElsevier$$c2024
000287484 3367_ $$2DRIVER$$aarticle
000287484 3367_ $$2DataCite$$aOutput Types/Journal article
000287484 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706881044_10984
000287484 3367_ $$2BibTeX$$aARTICLE
000287484 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287484 3367_ $$00$$2EndNote$$aJournal Article
000287484 520__ $$aThe aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma.GMMG-HD6 was a phase 3, randomised trial conducted at 43 main trial sites and 26 associated trial sites throughout Germany. Adult patients (aged 18-70 years) with previously untreated, symptomatic multiple myeloma, and a WHO performance status of 0-3, with 3 being allowed only if caused by myeloma disease and not by comorbid conditions, were randomly assigned 1:1:1:1 to four treatment groups. Induction therapy consisted of four 21-day cycles of RVd (lenalidomide 25 mg orally on days 1-14; bortezomib 1·3 mg/m2 subcutaneously on days 1, 4, 8, and 11]; and dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11, 12, and 15 for cycles 1-2) or, RVd induction plus elotuzumab (10 mg/kg intravenously on days 1, 8, and 15 for cycles 1-2, and on days 1 and 11 for cycles 3-4; E-RVd). Autologous haematopoietic stem-cell transplantation was followed by two 21-day cycles of either RVd consolidation (lenalidomide 25 mg orally on days 1-14; bortezomib 1·3 mg/m2 subcutaneously on days 1, 8, and 15; and dexamethasone 20 mg orally on days 1, 2, 8, 9, 15, and 16) or elotuzumab plus RVd consolidation (with elotuzumab 10 mg/kg intravenously on days 1, 8, and 15) followed by maintenance with either lenalidomide (10 mg orally on days 1-28 for cycles 1-3; thereafter, up to 15 mg orally on days 1-28; RVd/R or E-RVd/R group) or lenalidomide plus elotuzumab (10 mg/kg intravenously on days 1 and 15 for cycles 1-6, and on day 1 for cycles 7-26; RVd/E-R or E-RVd/E-R group) for 2 years. The primary endpoint was progression-free survival analysed in a modified intention-to-treat (ITT) population. Safety was analysed in all patients who received at least one dose of trial medication. This trial is registered with ClinicalTrials.gov, NCT02495922, and is completed.Between June 29, 2015, and on Sept 11, 2017, 564 patients were included in the trial. The modified ITT population comprised 559 (243 [43%] females and 316 [57%] males) patients and the safety population 555 patients. After a median follow-up of 49·8 months (IQR 43·7-55·5), there was no difference in progression-free survival between the four treatment groups (adjusted log-rank p value, p=0·86), and 3-year progression-free survival rates were 69% (95% CI 61-77), 69% (61-76), 66% (58-74), and 67% (59-75) for patients treated with RVd/R, RVd/E-R, E-RVd/R, and E-RVd/E-R, respectively. Infections (grade 3 or worse) were the most frequently observed adverse event in all treatment groups (28 [20%] of 137 for RVd/R; 32 [23%] of 138 for RVd/E-R; 35 [25%] of 138 for E-RVd/R; and 48 [34%] of 142 for E-RVd/E-R). Serious adverse events (grade 3 or worse) were observed in 68 (48%) of 142 participants in the E-RVd/E-R group, 53 (39%) of 137 in the RVd/R, 53 (38%) of 138 in the RVd/E-R, and 50 (36%) of 138 in the E-RVd/R (36%) group. There were nine treatment-related deaths during the study. Two deaths (one sepsis and one toxic colitis) in the RVd/R group were considered lenalidomide-related. One death in the RVd/E-R group due to meningoencephalitis was considered lenalidomide and elotuzumab-related. Four deaths (one pulmonary embolism, one septic shock, one atypical pneumonia, and one cardiovascular failure) in the E-RVd/R group and two deaths (one sepsis and one pneumonia and pulmonary fibrosis) in the E-RVd/E-R group were considered related to lenalidomide or elotuzumab, or both.Addition of elotuzumab to RVd induction or consolidation and lenalidomide maintenance in patients with transplant-eligible newly diagnosed multiple myeloma did not provide clinical benefit. Elotuzumab-containing therapies might be reserved for patients with relapsed or refractory multiple myeloma.Bristol Myers Squibb/Celgene and Chugai.
000287484 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000287484 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287484 7001_ $$aGoldschmid, Hartmut$$b1
000287484 7001_ $$0P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aMiah, Kaya$$b2$$udkfz
000287484 7001_ $$aBertsch, Uta$$b3
000287484 7001_ $$aBesemer, Britta$$b4
000287484 7001_ $$aHänel, Mathias$$b5
000287484 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b6$$udkfz
000287484 7001_ $$aFenk, Roland$$b7
000287484 7001_ $$aSchlenzka, Jana$$b8
000287484 7001_ $$aMunder, Markus$$b9
000287484 7001_ $$aDürig, Jan$$b10
000287484 7001_ $$aBlau, Igor W$$b11
000287484 7001_ $$aHuhn, Stefanie$$b12
000287484 7001_ $$aHose, Dirk$$b13
000287484 7001_ $$aJauch, Anna$$b14
000287484 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b15
000287484 7001_ $$aMann, Christoph$$b16
000287484 7001_ $$aWeinhold, Niels$$b17
000287484 7001_ $$aScheid, Christof$$b18
000287484 7001_ $$aSchroers, Roland$$b19
000287484 7001_ $$avon Metzler, Ivana$$b20
000287484 7001_ $$aSchieferdecker, Aneta$$b21
000287484 7001_ $$aThomalla, Jörg$$b22
000287484 7001_ $$aReimer, Peter$$b23
000287484 7001_ $$aMahlberg, Rolf$$b24
000287484 7001_ $$aGraeven, Ullrich$$b25
000287484 7001_ $$aKremers, Stephan$$b26
000287484 7001_ $$aMartens, Uwe M$$b27
000287484 7001_ $$aKunz, Christian$$b28
000287484 7001_ $$aHensel, Manfred$$b29
000287484 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b30$$udkfz
000287484 7001_ $$aSeidel-Glätzer, Andrea$$b31
000287484 7001_ $$aWeisel, Katja C$$b32
000287484 7001_ $$aRaab, Marc S$$b33
000287484 7001_ $$aSalwender, Hans J$$b34
000287484 7001_ $$aGroup, German-speaking Myeloma Multicenter$$b35$$eCollaboration Author
000287484 7001_ $$aAdrian, Nicole$$b36$$eContributor
000287484 7001_ $$aBernhard, Helga$$b37$$eContributor
000287484 7001_ $$aBöck, Hans-Peter$$b38$$eContributor
000287484 7001_ $$aBolling, Claus$$b39$$eContributor
000287484 7001_ $$aDingeldein, Gerrit$$b40$$eContributor
000287484 7001_ $$aEmde, Till-Oliver$$b41$$eContributor
000287484 7001_ $$aFerstl, Barbara$$b42$$eContributor
000287484 7001_ $$aFietz, Thomas$$b43$$eContributor
000287484 7001_ $$aFronhoffs, Stefan$$b44$$eContributor
000287484 7001_ $$aFuhrmann, Stephan$$b45$$eContributor
000287484 7001_ $$aFuxius, Stefan$$b46$$eContributor
000287484 7001_ $$aGeer, Thomas$$b47$$eContributor
000287484 7001_ $$aGörner, Martin$$b48$$eContributor
000287484 7001_ $$aGuenther, Barbara$$b49$$eContributor
000287484 7001_ $$aHartmann, Frank$$b50$$eContributor
000287484 7001_ $$aHeilmeier, Bernhard$$b51$$eContributor
000287484 7001_ $$aHeinsch, Michael$$b52$$eContributor
000287484 7001_ $$aHoffmann, Martin$$b53$$eContributor
000287484 7001_ $$aHolderried, Tobias A W$$b54$$eContributor
000287484 7001_ $$aKlein, Stefan$$b55$$eContributor
000287484 7001_ $$aKlump, Martin$$b56$$eContributor
000287484 7001_ $$aKnauf, Wolfgang$$b57$$eContributor
000287484 7001_ $$aLa Rosée, Paul$$b58$$eContributor
000287484 7001_ $$aLange, Elisabeth$$b59$$eContributor
000287484 7001_ $$aLindemann, Walter$$b60$$eContributor
000287484 7001_ $$aLopez, Roderico$$b61$$eContributor
000287484 7001_ $$aMayer, Frank$$b62$$eContributor
000287484 7001_ $$aNückel, Holger$$b63$$eContributor
000287484 7001_ $$aPapesch, Eva$$b64$$eContributor
000287484 7001_ $$aProcaccianti, Maria$$b65$$eContributor
000287484 7001_ $$aReichart, Alexander$$b66$$eContributor
000287484 7001_ $$aRummel, Mathias$$b67$$eContributor
000287484 7001_ $$aScheuer, Lars$$b68$$eContributor
000287484 7001_ $$aSchmitt, Hans-Roland$$b69$$eContributor
000287484 7001_ $$aStaib, Peter$$b70$$eContributor
000287484 7001_ $$aSteiniger, Heike$$b71$$eContributor
000287484 7001_ $$aTischler, Hans-Joachim$$b72$$eContributor
000287484 7001_ $$aUlshöfer, Thomas$$b73$$eContributor
000287484 7001_ $$aVerbeek, Walter$$b74$$eContributor
000287484 7001_ $$aWacker, Alexander$$b75$$eContributor
000287484 7001_ $$aZirpel, Iris$$b76$$eContributor
000287484 773__ $$0PERI:(DE-600)2802056-X$$a10.1016/S2352-3026(23)00366-6$$gVol. 11, no. 2, p. e101 - e113$$n2$$pe101 - e113$$tThe lancet / Haematology$$v11$$x2352-3026$$y2024
000287484 8564_ $$uhttps://inrepo02.dkfz.de/record/287484/files/1-s2.0-S2352302623003666-main.pdf
000287484 8564_ $$uhttps://inrepo02.dkfz.de/record/287484/files/1-s2.0-S2352302623003666-main.pdf?subformat=pdfa$$xpdfa
000287484 909CO $$ooai:inrepo02.dkfz.de:287484$$pVDB
000287484 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000287484 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000287484 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000287484 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000287484 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000287484 9141_ $$y2024
000287484 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET HAEMATOL : 2022$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000287484 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bLANCET HAEMATOL : 2022$$d2023-08-26
000287484 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000287484 980__ $$ajournal
000287484 980__ $$aVDB
000287484 980__ $$aI:(DE-He78)C060-20160331
000287484 980__ $$aUNRESTRICTED